▽ Sort by :: Latest

Search articles

Filter

October 2026

News - CMN Webinar - History of Genome Safety & Regulatory Requirements

crisprmedicinenews.com· Oct 22·Gene Editing·CRISPR·Gene editing·Webinar·44

Oct 22

Roivant, continuing ascent, claims another victory for rare disease drug

www.biopharmadive.com· Oct 21·Clinical Trial·Phase 2·Phase 3·42

Oct 21

Rapport’s epilepsy drug finds surprising success in bipolar trial

www.biopharmadive.com· Oct 20·Clinical Trial·Phase 2·Phase 3·Positive data·76

Oct 20

Most new drugs are still too costly at launch, ICER says

Insmed, Inc. · INSM·Merck & Co., Inc. · MRK·Johnson & Johnson · JNJ

www.biopharmadive.com· Oct 20·Gene Editing·CAR T·CRISPR·Gene editing·86

Oct 20

Hype vs. reality: What pharma’s hottest R&D bets have actually proved

www.biopharmadive.com· Oct 20·Cell Therapy·CAR T·First In Human·Phase 1·100

Oct 20

Disc’s once-spurned rare disease drug to get a second chance at approval

www.biopharmadive.com· Oct 19·Clinical Trial·Complete response·Phase 2·Phase 3·57

Oct 19

Merck KGaA bets on RNAi with $1.3B Silence buyout

www.biopharmadive.com· Oct 19·Clinical Trial·Phase 2·Phase 3·42

Oct 19

Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study

www.biopharmadive.com· Oct 19·Gene Therapy·Gene therapy·Phase 3·54

Oct 19

From strategy to scale: How Saudi Arabia is building a biotech ecosystem

Thermo Fisher Scientific, Inc. · TMO·Tiziana Life Sciences Ltd. Common Shares · TLSA·AstraZeneca PLC · AZN

www.biopharmadive.com· Oct 19·Gene Editing·Cell therapy·Gene editing·Gene therapy·100

Oct 19

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

www.genengnews.com· Oct 18·Peptide·Conference·GLP 1·NCT03878459·62

Oct 18

News - CARBON Newsletter (16 October 2026) - Your Latest News About CRISPR in AgroBio

Vylor Inc. · VYLR·Corteva, Inc. · CTVA

crisprmedicinenews.com· Oct 16·Gene Editing·Base editing·CRISPR·Gene editing·100

Oct 16

Belgian startup revives Galapagos CAR-T research

www.biopharmadive.com· Oct 15·Cell Therapy·CAR T·Cell therapy·56

Oct 15

Iambic, an AI drug discovery specialist, banks $150M in an IPO

www.biopharmadive.com· Oct 15·Cell Therapy·Cell therapy·Phase 1·40

Oct 15

Cell Therapy Manufacturing Takes Shape Across Asia-Pacific

www.genengnews.com· Oct 14·Gene Therapy·Cell therapy·Gene therapy·58

Oct 14

News - Base Editor Restores Glucose Production in GSDIa Patients

crisprmedicinenews.com· Oct 14·Gene Editing·Base editing·Cell therapy·CRISPR·92

Oct 14

First Tracks climbs on ‘impressive’ celiac study data

www.biopharmadive.com· Oct 12·Clinical Trial·Phase 2·Statistically significant·40

Oct 12

StockWatch: Caribou Plunges as It Pursues Strategic Alternatives

Caribou Biosciences, Inc. · CRBU·ABBVIE INC. · ABBV·Biogen Inc. · BIIB

www.genengnews.com· Oct 12·Gene Editing·CAR T·Cell therapy·Complete response·100

Oct 12

Bristol Myers dips on ‘confounding’ lung drug results

www.biopharmadive.com· Oct 12·Clinical Trial·Phase 2·Phase 3·42

Oct 12

News - Base Editing Mitigates Progeria Vessel Defects

crisprmedicinenews.com· Oct 12·Gene Editing·Base editing·CRISPR·62

Oct 12

News - CMN Webinar - Expert Discussion: Rethinking Cell & Gene Therapy Safety

crisprmedicinenews.com· Oct 12·Gene Editing·CRISPR·Gene editing·Gene therapy·70

Oct 12

FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts

www.biopharmadive.com· Oct 09·Fda Approval·FDA approval·Gene therapy·GLP 1·100

Oct 09

Argenx falls as Sjögren’s setback offsets celiac drug progress

www.biopharmadive.com· Oct 08·Clinical Trial·Phase 2·Phase 3·42

Oct 08

In the hunt for reverse merger targets, Caribou could be prized game

www.biopharmadive.com· Oct 08·Gene Editing·Cell therapy·CRISPR·Gene editing·84

Oct 08

Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

www.biopharmadive.com· Oct 07·Gene Editing·CAR T·Cell therapy·CRISPR·100

Oct 07

News - Preclinical: Prime Editing Restores GATA2-Deficient Patient Stem Cells

crisprmedicinenews.com· Oct 07·Gene Editing·CRISPR·Prime editing·62

Oct 07

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

www.biopharmadive.com· Oct 06·Clinical Trial·Phase 2·Phase 3·42

Oct 06

The top biopharma conferences in 2027

www.biopharmadive.com· Oct 06·Gene Therapy·Cell therapy·Conference·Gene therapy·86

Oct 06

News - Clinical: FDA Backs Single-Trial Pathway for Wave’s AATD RNA Editor

crisprmedicinenews.com· Oct 05·Gene Editing·Base editing·CRISPR·62

Oct 05

3 takeaways from a European obesity scientific meeting

www.biopharmadive.com· Oct 01·Peptide·GLP 1·Phase 1·Phase 2·60

Oct 01

September 2026

PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval

www.biopharmadive.com· Sep 30·Cell Therapy·Cell therapy·Phase 3·50

Sep 30

News - Cargo-Sized Lipid Screen Extends Gene Editing Beyond the Liver

crisprmedicinenews.com· Sep 30·Gene Editing·CRISPR·Gene editing·62

Sep 30

Beam sues 2 biotechs, alleging theft of base editing trade secrets

www.biopharmadive.com· Sep 29·Gene Editing·Base editing·Gene editing·Phase 2·72

Sep 29

Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

www.biopharmadive.com· Sep 29·Peptide·GLP 1·Phase 1·70

Sep 29

UniQure tumbles with latest data for Huntington’s gene therapy

www.biopharmadive.com· Sep 29·Gene Therapy·Gene therapy·Phase 3·54

Sep 29

An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus

www.biopharmadive.com· Sep 28·Cell Therapy·CAR T·Cell therapy·Complete response·71

Sep 28

Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

www.biopharmadive.com· Sep 28·Clinical Trial·Phase 2·Phase 3·42

Sep 28

This week in charts: Novo’s rise and fall and AI biotechs’ big haul

www.biopharmadive.com· Sep 25·Peptide·GLP 1·Phase 1·46

Sep 25

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

Acadia Pharmaceuticals Inc. · ACAD·Eli Lilly & Co. · LLY·Nektar Therapeutics · NKTR

www.biopharmadive.com· Sep 25·Clinical Trial·Phase 2·Phase 3·42

Sep 25

News - CMN Weekly (25 September 2026) - Your Weekly CRISPR Medicine News

Intellia Therapeutics, Inc · NTLA·CRISPR Therapeutics AG · CRSP·Beam Therapeutics Inc. · BEAM

crisprmedicinenews.com· Sep 25·Gene Editing·Base editing·CAR T·CRISPR·100

Sep 25

Grail multicancer detection test wins FDA advisers’ backing

www.biopharmadive.com· Sep 24·Fda Approval·FDA approval·44

Sep 24

Merck reveals study success, and possible safety worries, for eye drug hopeful

www.biopharmadive.com· Sep 24·Clinical Trial·Phase 2·Pivotal trial·42

Sep 24

Lilly’s latest China drug deal; Immunovant’s setback in lupus

www.biopharmadive.com· Sep 24·Clinical Trial·Phase 2·Phase 3·Statistically significant·58

Sep 24

Enveda, an AI drugmaker, banks $311M in venture funding

www.biopharmadive.com· Sep 23·Peptide·GLP 1·Phase 1·Phase 2·60

Sep 23

News - Preclinical: Targeted DNA Insertion Preserves Vision in Mice With Retinitis Pigmentosa

crisprmedicinenews.com· Sep 23·Gene Editing·CRISPR·Peptide·62

Sep 23

Amgen reports a Phase 3 win with Sjögren’s drug candidate

www.biopharmadive.com· Sep 22·Clinical Trial·Phase 2·Phase 3·Statistically significant·58

Sep 22

Viking shares surge on updated obesity drug data

www.biopharmadive.com· Sep 22·Peptide·GLP 1·Phase 2·Phase 3·70

Sep 22

Celldex sinks as safety concerns cloud immune drug results

www.biopharmadive.com· Sep 22·Fda Approval·Complete response·Conference·FDA approval·69

Sep 22

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

ABBVIE INC. · ABBV·Cue Biopharma, Inc. · CUE·Johnson & Johnson · JNJ

www.biopharmadive.com· Sep 22·Clinical Trial·Phase 2·Phase 3·42

Sep 22

Beacon eye gene therapy hits mark in late-stage study

www.biopharmadive.com· Sep 21·Gene Therapy·Gene therapy·Pivotal trial·Statistically significant·70

Sep 21

Novo talks up drug launches in effort to win back investors

www.biopharmadive.com· Sep 21·Peptide·GLP 1·Phase 2·52

Sep 21

News - Base editing expands its scope through advances in editor design

crisprmedicinenews.com· Sep 21·Gene Editing·Base editing·CRISPR·In vivo editing·84

Sep 21

Xenon shares fall following depression trial pause

Xenon Pharmaceuticals Inc · XENE

www.biopharmadive.com· Sep 18·Clinical Trial·Phase 2·Phase 3·42

Sep 18

Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug

www.biopharmadive.com· Sep 18·Gene Therapy·Cell therapy·Gene therapy·Phase 1·96

Sep 18

News - CARBON Newsletter (18 September 2026) - Your Latest News About CRISPR in AgroBio

crisprmedicinenews.com· Sep 18·Gene Editing·Base editing·CRISPR·Gene editing·86

Sep 18

Sling banks $123M for an experimental thyroid eye disease pill

www.biopharmadive.com· Sep 16·Clinical Trial·Phase 3·Statistically significant·44

Sep 16

FDA clears first generic radioligand drug; Sionna turns to layoffs

www.biopharmadive.com· Sep 15·Peptide·GLP 1·Phase 2·52

Sep 15

Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing

AstraZeneca PLC · AZN·Iovance Biotherapeutics, Inc. · IOVA·Novartis AG · NVS

www.biopharmadive.com· Sep 14·Gene Editing·Base editing·CAR T·Cell therapy·100

Sep 14

News - Dense RNA modifications boost prime editing in mice

crisprmedicinenews.com· Sep 14·Gene Editing·CRISPR·Prime editing·62

Sep 14

News - CMN Moderates Panel Discussion at CSGCT 2026 – In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale

crisprmedicinenews.com· Sep 14·Gene Editing·Cell therapy·CRISPR·Gene therapy·100

Sep 14

News - CMN Moderate Panel Discussion at CSGCT 2026: In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale

crisprmedicinenews.com· Sep 14·Gene Editing·CRISPR·Gene therapy·In vivo editing·86

Sep 14

Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

www.biopharmadive.com· Sep 11·Gene Therapy·Gene therapy·Phase 2·Phase 3·84

Sep 11

mRNA cancer vaccines’ biggest barriers to market

www.biopharmadive.com· Sep 11·Fda Approval·FDA approval·Phase 2·Phase 3·86

Sep 11

CAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research Collaboration

www.genengnews.com· Sep 10·Cell Therapy·CAR T·Cell therapy·56

Sep 10

News - CRISPR Trials Global Overview Q2 2026 from CMN Intelligence: 300+ Gene Editing Trials in the World's Only Manually Curated Global Database

crisprmedicinenews.com· Sep 10·Gene Editing·CRISPR·Gene editing·62

Sep 10

News - CMN Intelligence Q2 2026 Update: 300+ CRISPR - Gene Editing Trials in the World's Only Manually Curated Global Database

crisprmedicinenews.com· Sep 10·Gene Editing·CRISPR·Gene editing·62

Sep 10

News - CMN Intelligence Q2 2026 Update: 300+ Gene-Editing Trials in the World's Only Manually Curated Global Database

crisprmedicinenews.com· Sep 10·Gene Editing·CRISPR·Gene editing·62

Sep 10

News - xx

crisprmedicinenews.com· Sep 10·Gene Editing·CRISPR·Gene editing·62

Sep 10

Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

Bristol-Myers Squibb Co. · BMY·AstraZeneca PLC · AZN·Merck & Co., Inc. · MRK

www.biopharmadive.com· Sep 08·Cell Therapy·CAR T·Cell therapy·Phase 2·100

Sep 08

Moonwalk reloads with $70M and new RNAi prospects for obesity

ADARx Pharmaceuticals, Inc. · ADRX·Wave Life Sciences Ltd. Ordinary Shares · WVE·Eli Lilly & Co. · LLY

www.biopharmadive.com· Sep 08·Gene Editing·Gene editing·GLP 1·SiRNA·80

Sep 08

BrainChild hauls in $116M to make cell therapies for childhood brain cancers

www.biopharmadive.com· Sep 08·Cell Therapy·CAR T·Cell therapy·Phase 2·70

Sep 08

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

ABBVIE INC. · ABBV·Johnson & Johnson · JNJ·Pfizer Inc. · PFE

www.biopharmadive.com· Sep 04·Cell Therapy·CAR T·Phase 3·52

Sep 04

This week in charts: China deals, stock flatlines and Lilly’s M&A spree

Alumis Inc. · ALMS·Ultragenyx Pharmaceutical Inc. · RARE·Eli Lilly & Co. · LLY

www.biopharmadive.com· Sep 04·Gene Therapy·Gene therapy·GLP 1·Phase 1·90

Sep 04

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

Pfizer Inc. · PFE·Ionis Pharmaceuticals, Inc. · IONS·Climb Bio, Inc. · CLYM

www.biopharmadive.com· Sep 04·Cell Therapy·CAR T·Cell therapy·Phase 1·96

Sep 04

News - Redesigned Landing Sites Lift Bxb1 Integration Efficiency

crisprmedicinenews.com· Sep 04·Gene Editing·CRISPR·Prime editing·62

Sep 04

Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study

Ionis Pharmaceuticals, Inc. · IONS

www.biopharmadive.com· Sep 03·Gene Therapy·Gene therapy·Phase 3·54

Sep 03

The hidden scale-out problem behind CAR-T’s growth

Legend Biotech Corporation · LEGN·Johnson & Johnson · JNJ·Novartis AG · NVS

www.biopharmadive.com· Sep 03·Cell Therapy·CAR T·Cell therapy·Phase 1·64

Sep 03

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Novartis AG · NVS·Bristol-Myers Squibb Co. · BMY·Allogene Therapeutics, Inc. · ALLO

www.biopharmadive.com· Sep 02·Gene Editing·CAR T·Cell therapy·CRISPR·84

Sep 02

UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy

Moderna, Inc. · MRNA

www.biopharmadive.com· Sep 02·Fda Approval·FDA approval·Gene therapy·80

Sep 02

Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

www.biopharmadive.com· Sep 02·Clinical Trial·Phase 2·Phase 3·Statistically significant·58

Sep 02

August 2026

Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Novartis AG · NVS·Bristol-Myers Squibb Co. · BMY

www.biopharmadive.com· Aug 31·Cell Therapy·CAR T·Cell therapy·Phase 1·64

Aug 31

StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy

www.genengnews.com· Aug 30·Fda Approval·FDA approval·NCT06625320·44

Aug 30

CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial

www.genengnews.com· Aug 28·Cell Therapy·CAR T·Cell therapy·56

Aug 28

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

AstraZeneca PLC · AZN·Ionis Pharmaceuticals, Inc. · IONS·Pfizer Inc. · PFE

www.biopharmadive.com· Aug 28·Clinical Trial·Pivotal trial·Statistically significant·44

Aug 28

News - CMN Weekly (28 August 2026) - Your Weekly CRISPR Medicine News

Fate Therapeutics, Inc. · FATE·Beam Therapeutics Inc. · BEAM·AstraZeneca PLC · AZN

crisprmedicinenews.com· Aug 28·Gene Editing·Base editing·Cell therapy·CRISPR·100

Aug 28

New data could widen use of AstraZeneca, Amgen immune disease drug

AstraZeneca PLC · AZN·Amgen Inc · AMGN

www.biopharmadive.com· Aug 27·Fda Approval·Expanded approval·Phase 3·Statistically significant·72

Aug 27

Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial

Eli Lilly & Co. · LLY·Summit Therapeutics Inc. · SMMT·Johnson & Johnson · JNJ

www.biopharmadive.com· Aug 26·Fda Approval·FDA approval·Phase 2·Phase 3·100

Aug 26

News - UNCOVERseq exposes off-targets missed by established standards

crisprmedicinenews.com· Aug 26·Gene Editing·CRISPR·Gene editing·62

Aug 26

FDA extends review of Capricor cell therapy; Pain drug startup to go public

Capricor Therapeutics Inc · CAPR·Werewolf Therapeutics, Inc. · HOWL·Ionis Pharmaceuticals, Inc. · IONS

www.biopharmadive.com· Aug 24·Gene Therapy·Cell therapy·Functional cure·54

Aug 24

Roche commits to lean-mass preservation with Hanmi obesity deal

Eli Lilly & Co. · LLY·Pfizer Inc. · PFE

www.biopharmadive.com· Aug 24·Peptide·GLP 1·Phase 1·46

Aug 24

News - CARBON Newsletter (21 August 2026) - Your Latest News About CRISPR in AgroBio

crisprmedicinenews.com· Aug 21·Gene Editing·CRISPR·Gene editing·Prime editing·100

Aug 21

Ultragenyx, after setbacks, nabs first gene therapy approval

www.biopharmadive.com· Aug 20·Fda Approval·Conference·FDA approval·Gene therapy·80

Aug 20

Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma

Moderna, Inc. · MRNA·Merck & Co., Inc. · MRK

www.biopharmadive.com· Aug 19·Clinical Trial·Phase 2·Phase 3·Statistically significant·58

Aug 19

Leo Pharma buys rare skin disease drug in $435M deal

www.biopharmadive.com· Aug 18·Gene Therapy·Gene therapy·Phase 3·54

Aug 18

News - In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale

crisprmedicinenews.com· Aug 18·Gene Editing·Cell therapy·CRISPR·Gene editing·92

Aug 18

Argenx jumps on Phase 3 data for blockbuster Vyvgart

argenx SE · ARGX

www.biopharmadive.com· Aug 17·Clinical Trial·Phase 3·Positive data·46

Aug 17

News - Triple Base Editor Diversifies Three Nucleotides at Once

crisprmedicinenews.com· Aug 17·Gene Editing·Base editing·CRISPR·62

Aug 17

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

Bristol-Myers Squibb Co. · BMY·Johnson & Johnson · JNJ·Amgen Inc · AMGN

www.biopharmadive.com· Aug 14·Fda Approval·FDA approval·Phase 3·72

Aug 14

News - Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy

Allogene Therapeutics, Inc. · ALLO

crisprmedicinenews.com· Aug 14·Gene Editing·Cell therapy·CRISPR·60

Aug 14

News - Founder, Jens-Ole Bock, CMN, Keynote Speaker at the CRISPR Gene Editing Hands-on Workshop at University of Lagos, Nigeria

crisprmedicinenews.com· Aug 14·Gene Editing·CRISPR·Gene editing·62

Aug 14

New Taiho, Cullian data heats up lung cancer drug battle

Johnson & Johnson · JNJ·AstraZeneca PLC · AZN

www.biopharmadive.com· Aug 13·Clinical Trial·Phase 2·Phase 3·Statistically significant·58

Aug 13